Tobin Schilke
CIK 1678984 · Chief Financial Officer · last filed 2026-03-04
Tobin Schilke is a Chief Financial Officer who has filed 54 SEC Form 4 insider transactions across 3 companies since 2016. The most recent filing shows the insider sold $266.3K of CRNX on Mar 4, 2026. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.69M
3
54
-$2.43M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Chief Financial Officer | 78,121 | $34.47 | $2.69M | -$266.3K | 3 | 2026-03-04 |
| Revance Therapeutics, Inc. (RVNC) Delisted | CFO | 0 | $3.65 | $0 | -$2.07M | 43 | 2025-02-06 |
| Achaogen, Inc. (AKAO) Delisted | Chief Financial Officer | 48,046 | — | — | -$100.1K | 8 | 2018-06-28 |
Recent Filings
54 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-04 | CRNX | Sell (S) | −6,713 | -$266.3K | EDGAR |
| 2026-02-25 | CRNX | Grant (A) | +32,000 | $0 | EDGAR |
| 2025-03-11 | CRNX | Grant (A) | +52,000 | $0 | EDGAR |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −201,554 | -$357.7K | EDGAR |
| 2025-02-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +6,888 | $0 | EDGAR |
| 2025-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +1,000 | $2.2K | EDGAR |
| 2024-07-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +1,000 | $2.2K | EDGAR |
| 2024-03-19 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −13,183 | -$67.5K | EDGAR |
| 2024-03-04 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +17,447 | $0 | EDGAR |
| 2024-02-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +96,667 | $0 | EDGAR |